December 8, 2006 -- GlaxoSmithKline will buy privately held antibody firm Domantis for $454 million; Encysive received permission to re-start clinical trials for its resistant hypertension drug; Genasense from Genta failed a Phase III test for myelogenous leukemia; Pfizer successfully beat back a patent assault on Lipitor in Canada; Coley Pharma altered its agreement with GlaxoSmithKline over the use of a vaccine adjuvant; GTx said ostarine, a selective androgen receptor modulator, produced positive data in a double-blind Phase II trial; and Cell Therapeutics ended a trial of Xyotax in patients with lung cancer. The Centient Biotech 200™ gained 16 points to end at 3987, an increase of .40%. More details...
